Correlation of plasma adipokines with endometrial atypical hyperplasia and type I/II endometrial cancer

References

• Ando, S., et al., 2019. Obesity, leptin and breast cancer: epidemiological evidence and proposed mechanisms. Cancers, 1 (11).
   Google Scholar
• Ashizawa, N., 2010. Serum leptin-adiponectin ratio and endometrial cancer risk in postmenopausal female subjects. Gynecologic Oncology, 119 (1), 65–69.
   PubMed Web of Science ®Google Scholar
• Bhan, V., et al., 2010. Relation between obesity and the attainment of optimal blood pressure and lipid targets in high vascular risk outpatients. The American Journal of Cardiology, 106 (9), 1270–1276.
   PubMed Web of Science ®Google Scholar
• Capozzi, V.A., et al., 2022. Nodal assessment in endometrial atypical hyperplasia. Gynecologic and Obstetric Investigation, 87 (3–4), 226–231.
   PubMed Web of Science ®Google Scholar
• Catalano, S., et al., 2009. Evidence that leptin through STAT and CREB signaling enhances cyclin D1 expression and promotes human endometrial cancer proliferation. Journal of Cellular Physiology, 218 (3), 490–500.
   PubMed Web of Science ®Google Scholar
• Chang, Y.H., et al., 2011. Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review. Diabetes/Metabolism Research and Reviews, 27 (6), 515–527.
   PubMed Web of Science ®Google Scholar
• Costales, A.B., et al., 2014. Clinically significant endometrial cancer risk following a diagnosis of complex atypical hyperplasia. Gynecologic Oncology, 135 (3), 451–454.
   PubMed Web of Science ®Google Scholar
• Cymbaluk-Płoska, A., et al., 2018. Evaluation of biologically active substances promoting the development of or protecting against endometrial cancer. OncoTargets and Therapy, 11, 1363–1372.
   PubMed Web of Science ®Google Scholar
• Feng, R., et al., 2014. Higher vaspin levels in subjects with obesity and type 2 diabetes mellitus: a meta-analysis. Diabetes Research and Clinical Practice, 106 (1), 88–94.
   PubMed Web of Science ®Google Scholar
• Fukuhara, A., et al., 2005. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science, 307 (5708), 426–430.
   PubMed Web of Science ®Google Scholar
• Gao, J., et al., 2009. Leptin induces functional activation of cyclooxygenase-2 through JAK2/STAT3, MAPK/ERK, and PI3K/AKT pathways in human endometrial cancer cells. Cancer Science, 100 (3), 389–395.
   PubMed Web of Science ®Google Scholar
• Gharibeh, M.Y., et al., 2010. Correlation of plasma resistin with obesity and insulin resistance in type 2 diabetic patients. Diabetes & Metabolism, 36 (6 Pt 1), 443–449.
   PubMed Web of Science ®Google Scholar
• Gitt, A., et al., 2012. Treatment patterns and risk factor control in patients with and without metabolic syndrome in cardiac rehabilitation. Vascular Health and Risk Management, 8, 265–274.
   PubMedGoogle Scholar
• Hanley, A.J., et al., 2007. Associations of adiponectin with body fat distribution and insulin sensitivity in nondiabetic Hispanics and African-Americans. The Journal of Clinical Endocrinology and Metabolism, 92 (7), 2665–2671.
   PubMed Web of Science ®Google Scholar
• Hida, K. W., et al., 2005. Visceral adipose tissue-derived serine protease inhibitor: A unique insulin-sensitizing adipocytokine in obesity. Proceedings of the National Academy of Sciences of the United States of America, 102 (30), 10610–10615.
   PubMed Web of Science ®Google Scholar
• Hlavna, M., et al., 2011. Relationship of resistin levels with endometrial cancer risk. Neoplasma, 58 (2), 124–128.
   PubMed Web of Science ®Google Scholar
• Ilhan, T.T., et al., 2015a. Relations of serum visfatin and resistin levels with endometrial cancer and factors associated with its prognosis. Asian Pacific Journal of Cancer Prevention, 16 (11), 4503–4508.
   PubMedGoogle Scholar
• Liu, Y., et al., 2011. Leptin activates STAT3 and ERK1/2 pathways and induces endometrial cancer cell proliferation. Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 31 (3), 365–370.
   PubMedGoogle Scholar
• Morciano, A., et al., 2014. Assessment of insulin resistance in lean women with polycystic ovary syndrome. Fertility and Sterility, 102 (1), 250–256.e3. e253.
   PubMed Web of Science ®Google Scholar
• Nakatsuka, A. W., et al., 2012. Vaspin is an adipokine ameliorating ER stress in obesity as a ligand for cell-surface GRP78/MTJ-1 complex. Diabetes, 61 (11), 2823–2832.
   PubMed Web of Science ®Google Scholar
• Nergiz Avcioglu, S., et al., 2015. Visfatin concentrations in patients with endometrial cancer. Gynecological Endocrinology : The Official Journal of the International Society of Gynecological Endocrinology, 31 (3), 202–207.
   PubMed Web of Science ®Google Scholar
• Setiawan, V.W., et al., 2013. Type I and II endometrial cancers: have they different risk factors? Journal of Clinical Oncology, (20)31, 2607–2618.
   PubMed Web of Science ®Google Scholar
• Tarkowski, A., et al., 2010. Resistin competes with lipopolysaccharide for binding to toll-like receptor 4. Journal of Cellular and Molecular Medicine, 14 (6B), 1419–1431.
   PubMed Web of Science ®Google Scholar
• Wang, C.H., et al., 2018. Resistin facilitates breast cancer progression via TLR4-mediated induction of mesenchymal phenotypes and stemness properties. Oncogene, 37 (5), 589–600.
   PubMed Web of Science ®Google Scholar
• Yadav, A., et al., 2013. Role of leptin and adiponectin in insulin resistance. Clinica Chimica Acta; International Journal of Clinical Chemistry, 417, 80–84.
   PubMed Web of Science ®Google Scholar
• Zhang, L., et al., 2015. Adiponectin mediates antiproliferative and apoptotic responses in endometrial carcinoma by the AdipoRs/AMPK pathway. Gynecologic Oncology, 137 (2), 311–320.
   PubMed Web of Science ®Google Scholar
• Zhang, Y., et al., 2014. Overweight, obesity and endometrial cancer risk: results from a systematic review and meta-analysis. The International Journal of Biological Markers, 29 (1), e21–e29.
   PubMed Web of Science ®Google Scholar